AM-36

[1]Callaway JK, et al. Delayed treatment with AM-36, a novel neuroprotective agent, reduces neuronal damage after endothelin-1-induced middle cerebral artery occlusion in conscious rats. Stroke. 1999 Dec;30 (12) :2704-12; discussion 2712.|[2]Callaway JK, et al. Incorporation of sodium channel blocking and free radical scavenging activities into a single drug, AM-36, results in profound inhibition of neuronal apoptosis. Br J Pharmacol. 2001 Apr;132 (8) :1691-8.|[3]Callaway JK, et al. AM-36, a novel neuroprotective agent, profoundly reduces reactive oxygen species formation and dopamine release in the striatum of conscious rats after endothelin-1-induced middle cerebral artery occlusion. Neuropharmacology. 2003 May;44 (6) :787-800.